Verastem Oncology, a biopharmaceutical company focused on cancer treatments, announced the pricing of an underwritten public offering. The offering includes 13,333,334 shares of common stock and accompanying warrants to purchase up to 13,333,334 shares at $3.00 per share and warrant.…
Bristol Myers Squibb today announced the validation of its near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi) as part of a mid-year update on its environmental initiatives. This milestone underscores the company’s progress in reducing emissions…
Roche announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for treating diabetic macular edema (DME) and diabetic retinopathy (DR), the leading causes of vision loss in adults with diabetes.…
Roche announced new, four-year data from the RHONE-X extension study today. The study met all primary endpoints, demonstrating that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years. The…
Roche announced positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. The data showed that participants with…
Revolution Medicines, a clinical-stage oncology company dedicated to targeting RAS-addicted cancers, has announced the publication of a peer-reviewed research paper in Cancer Discovery. The paper showcases the efficacy of their RAS(ON) multi-selective inhibitor, RMC-7977 (representative of investigational drug RMC-6236), in…
Global pharmaceutical leader Lupin Limited announced today that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Dabhasa, Gujarat. The EIR follows the inspection conducted from…
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company focused on developing and commercializing innovative products, announced a CEO succession plan effective August 1, 2024. Paul R. Edick will retire from his operational and Chairman roles after more than seven…
Cencora Announces Q3 Fiscal 2024 Earnings Release Date and Conference Call Cencora, Inc. (NYSE: COR) has announced plans to release its Third Quarter Fiscal 2024 results on Wednesday, July 31, 2024, before the New York Stock Exchange opens for trading.…
MDPI is delighted to announce the opening of nominations for the 2024 Tu Youyou Award, a prestigious recognition established in honor of Professor Tu Youyou, Nobel Laureate, whose discovery has significantly impacted the global fight against malaria. The Tu Youyou…
During its annual event “BIG UP,” French Tech Saint-Etienne Lyon awarded the BIG Start-up of the Year trophy to a start-up that exemplifies the region’s innovation and richness. French Tech Saint-Etienne Lyon, a non-profit association established in 2015, promotes the…
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that its Phase II/III SKYSCRAPER-06 study did not achieve its primary endpoints in evaluating tiragolumab in combination with Tecentriq® (atezolizumab) and chemotherapy compared to pembrolizumab and…